S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
S&P 500   4,229.45
DOW   33,002.38
QQQ   354.92
Warren Buffett's company dumps another 5 million shares of printer maker HP
The Strategic Gold Play You Haven't Heard About (Ad)
How You Can Beat the Yields on near 5% Treasuries, plus Upside
Low PE Growth Stocks: Unlocking Investment Opportunities
Would Buffett Approve of This Growth Strategy? (Ad)
3 Reliable Growing Dividends Near Rock-Bottom Prices
Why Ralph Lauren Should Be On Your Holiday Wishlist
The Strategic Gold Play You Haven't Heard About (Ad)
Stock market today: Wall Street futures inch higher as bond yields stabilize, oil prices slide
5 Short Squeeze Candidates With Catalysts For Rebounds
NASDAQ:NKTX

Nkarta (NKTX) Stock Forecast, Price & News

$1.37
+0.06 (+4.58%)
(As of 10/3/2023 ET)
Compare
Today's Range
$1.28
▼
$1.40
50-Day Range
$1.31
▼
$2.29
52-Week Range
$1.28
▼
$14.57
Volume
502,444 shs
Average Volume
465,061 shs
Market Capitalization
$67.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Nkarta MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
1,262.5% Upside
$18.67 Price Target
Short Interest
Bearish
6.52% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.17mentions of Nkarta in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$2,436 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.83) to ($2.86) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Medical Sector

628th out of 967 stocks

Biotechnology Industry

26th out of 43 stocks

See Top Rated MarketRank™ Stocks Here

NKTX stock logo

About Nkarta (NASDAQ:NKTX) Stock

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

NKTX Price History

NKTX Stock News Headlines

October 2, 2023 | americanbankingnews.com
Analysts Offer Predictions for Nkarta, Inc.'s Q3 2023 Earnings (NASDAQ:NKTX)
September 28, 2023 | markets.businessinsider.com
Promising Prospects for Ventyx Biosciences: A Comprehensive Analysis of VTX002’s Potential in Ulcerative Colitis Treatment
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
September 9, 2023 | benzinga.com
Nkarta Stock (NASDAQ:NKTX), Analyst Ratings, Price Targets, Predictions
August 14, 2023 | nasdaq.com
Mizuho Maintains Nkarta (NKTX) Buy Recommendation
August 14, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX) and Ventyx Biosciences (VTYX)
August 11, 2023 | msn.com
HC Wainwright & Co. Reiterates Nkarta (NKTX) Buy Recommendation
August 11, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on Nkarta (NKTX)
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
August 11, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Nkarta
August 10, 2023 | finanznachrichten.de
Nkarta, Inc.: Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
August 10, 2023 | finance.yahoo.com
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
July 6, 2023 | msn.com
Nkarta (NKTX) Price Target Decreased by 25.24% to 20.02
July 5, 2023 | finance.yahoo.com
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
June 29, 2023 | msn.com
Raymond James Maintains Nkarta (NKTX) Outperform Recommendation
June 28, 2023 | finance.yahoo.com
Here's Why Nkarta, Inc. (NKTX) is Poised for a Turnaround After Losing -39.31% in 4 Weeks
June 28, 2023 | msn.com
HC Wainwright & Co. Maintains Nkarta (NKTX) Buy Recommendation
June 28, 2023 | msn.com
Needham Maintains Nkarta (NKTX) Buy Recommendation
June 27, 2023 | benzinga.com
Needham Maintains Buy on Nkarta, Lowers Price Target to $19
June 27, 2023 | bizjournals.com
Why Wall Street shaved a third of Peninsula cancer cell therapy company's value despite good news
June 27, 2023 | markets.businessinsider.com
NKX101's Leukemia Setting Phase 1 Results a Setback for Nkarta: Analyst Lowers Price Target Amid Revised Development Timeline
June 27, 2023 | markets.businessinsider.com
Needham Keeps Their Buy Rating on Nkarta (NKTX)
June 27, 2023 | msn.com
Nkarta's Updated Data From Leukemia Study Fails To Cheer Investors
June 27, 2023 | msn.com
Nkarta off 34% after updating early-stage data for leukemia therapy
June 27, 2023 | markets.businessinsider.com
Analyst Expectations for Nkarta's Future
June 27, 2023 | finance.yahoo.com
Why Shares of Nkarta Are Slumping Tuesday
June 27, 2023 | finance.yahoo.com
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
See More Headlines
Receive NKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nkarta and its competitors with MarketBeat's FREE daily newsletter.

NKTX Company Calendar

Last Earnings
8/10/2023
Today
10/04/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NKTX
CUSIP
N/A
CIK
1787400
Web
www.nkartatx.com
Phone
925-407-1049
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$18.67
High Stock Price Forecast
$26.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+1,262.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.56)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-113,840,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-34.83%
Return on Assets
-26.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.77
Quick Ratio
10.77

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.63 per share
Price / Book
0.18

Miscellaneous

Outstanding Shares
49,060,000
Free Float
46,311,000
Market Cap
$67.21 million
Optionable
Not Optionable
Beta
0.04
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Paul J. HastingsMr. Paul J. Hastings (Age 63)
    CEO, Pres & Director
    Comp: $938.41k
  • Dr. Alicia J. Hager (Age 53)
    Chief Legal Officer & Corp. Sec.
    Comp: $590.94k
  • Ms. Alyssa Levin C.A. (Age 38)
    CPA, Chief Financial & Bus. Officer and Principal Accounting Officer
  • Dr. Ralph Brandenberger Ph.D. (Age 54)
    Chief Technical Officer
  • Dr. James Trager Ph.D. (Age 59)
    Ph.D., Chief Scientific Officer
  • Ms. Yvonne Li M.B.A. (Age 63)
    Chief Admin. Officer
  • Mr. Greg Mann
    VP of Public Affairs and Investor Relations
  • Dr. David R. Shook M.D. (Age 45)
    Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













NKTX Stock - Frequently Asked Questions

Should I buy or sell Nkarta stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nkarta in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NKTX shares.
View NKTX analyst ratings or view top-rated stocks.

What is Nkarta's stock price forecast for 2023?

5 brokerages have issued 1 year target prices for Nkarta's stock. Their NKTX share price forecasts range from $15.00 to $26.00. On average, they expect the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 1,262.5% from the stock's current price.
View analysts price targets for NKTX or view top-rated stocks among Wall Street analysts.

How have NKTX shares performed in 2023?

Nkarta's stock was trading at $5.99 at the beginning of the year. Since then, NKTX shares have decreased by 77.1% and is now trading at $1.37.
View the best growth stocks for 2023 here.

When is Nkarta's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our NKTX earnings forecast.

How were Nkarta's earnings last quarter?

Nkarta, Inc. (NASDAQ:NKTX) posted its quarterly earnings results on Thursday, August, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01.

What other stocks do shareholders of Nkarta own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nkarta investors own include Axcella Health (AXLA), Cronos Group (CRON), Block (SQ), Advanced Micro Devices (AMD), ASML (ASML), Beyond Meat (BYND), Citigroup (C), Salesforce (CRM), CVS Health (CVS) and DraftKings (DKNG).

When did Nkarta IPO?

(NKTX) raised $150 million in an IPO on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. Cowen, Evercore ISI, Stifel and Mizuho Securities acted as the underwriters for the IPO.

What is Nkarta's stock symbol?

Nkarta trades on the NASDAQ under the ticker symbol "NKTX."

How do I buy shares of Nkarta?

Shares of NKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nkarta's stock price today?

One share of NKTX stock can currently be purchased for approximately $1.37.

How much money does Nkarta make?

Nkarta (NASDAQ:NKTX) has a market capitalization of $67.21 million. The company earns $-113,840,000.00 in net income (profit) each year or ($2.56) on an earnings per share basis.

How many employees does Nkarta have?

The company employs 169 workers across the globe.

How can I contact Nkarta?

Nkarta's mailing address is 6000 SHORELINE COURT SUITE 102, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.nkartatx.com. The company can be reached via phone at 925-407-1049 or via email at gmann@nkartatx.com.

This page (NASDAQ:NKTX) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -